Literature DB >> 1003647

Results of 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report.

N Firusian, P Mellin, C G Schmidt.   

Abstract

The therapeutic application of 89strontium for the relief of pain in 11 cases of carcinoma of the prostate with skeletal metastases is reported. A significant clinical improvement could be observed in 8 of the 11 patients with generalized osseous metastases of prostatic carcinoma after the application of 30 muCi. 89strontium per kg. The effect was long lasting. At the same time an increase of alkaline phosphatase was observed, which was interpreted as an indication of the reactivation of osteoblasts and osteoid peripheral zones owing to beta-emission of the radioisotope in the affected areas. The indications for such therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1003647     DOI: 10.1016/s0022-5347(17)59002-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  12 in total

Review 1.  Targeted radionuclide therapy for bone metastases.

Authors:  V J Lewington
Journal:  Eur J Nucl Med       Date:  1993-01

2.  Measurements of the strontium plasma clearance rate in patients receiving 89Sr radionuclide therapy.

Authors:  G M Blake; M A Zivanovic; V J Lewington
Journal:  Eur J Nucl Med       Date:  1989

3.  Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma.

Authors:  K Buchali; H J Correns; M Schuerer; D Schnorr; H Lips; K Sydow
Journal:  Eur J Nucl Med       Date:  1988

4.  89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma.

Authors:  G M Blake; J F Wood; P J Wood; M A Zivanovic; V J Lewington
Journal:  Eur J Nucl Med       Date:  1989

5.  Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody.

Authors:  Kelly Davis Orcutt; John J Rhoden; Benjamin Ruiz-Yi; John V Frangioni; K Dane Wittrup
Journal:  Mol Cancer Ther       Date:  2012-04-05       Impact factor: 6.261

6.  Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate.

Authors:  G M Blake; M A Zivanovic; A J McEwan; D M Ackery
Journal:  Eur J Nucl Med       Date:  1986

7.  89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma.

Authors:  G M Blake; M A Zivanovic; A J McEwan; V B Batty; D M Ackery
Journal:  Eur J Nucl Med       Date:  1987

8.  89Strontium therapy of bone metastases of carcinoma of the prostatic gland.

Authors:  H J Correns; M Mebel; K Buchali; D Schnorr; C Seidel; E Mitterlechner
Journal:  Eur J Nucl Med       Date:  1979-02-01

9.  Strontium 89 for palliation of bone metastases.

Authors:  E K Reddy; R G Robinson; C M Mansfield
Journal:  J Natl Med Assoc       Date:  1986-01       Impact factor: 1.798

10.  Samarium-153 EDTMP therapy of disseminated skeletal metastasis.

Authors:  J H Turner; A A Martindale; P Sorby; E L Hetherington; R F Fleay; R F Hoffman; P G Claringbold
Journal:  Eur J Nucl Med       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.